Intervacc has evaluated American strep bacteria strain ahead of clinical studies
The evaluation shows that the strain is identical to the European strain, enabling cost savings and time efficiencies ahead of US launch of Strangvac.
See the latest news and media coverage for Intervacc. We track all announcements, press releases, and industry mentions in real time, all in one place.
Swedish animal health vaccine developer
intervacc.seLast updated
In short: Intervacc advanced its Strangvac vaccine clinical trials in the US, reported mixed financial results, and appointed new executive leadership.
The evaluation shows that the strain is identical to the European strain, enabling cost savings and time efficiencies ahead of US launch of Strangvac.
Net sales decreased and operating profit deteriorated.
The vaccine against horse strangles is approved for sale by Icelandic authorities despite a general vaccination ban. It protects exported horses and enables disease surveillance.
The annual report for the 2025 fiscal year is available on the website intervacc.se. The information was disclosed on April 14, 2026.
This article first appeared on GuruFocus. Intervacc AB (OSTO:IVACC) is set to release its Q1 2026 earnings on May 13, 2026. The consensus estimate for...
Intervacc AB (publ) announces that Strangvac, the company's innovative vaccine against strangles in horses, has been approved by the authorities in Iceland. Strangles, a potentially...
Intervacc AB (publ) is first in the world to show that piglets were protected against the virulent and severe disease-causing S. suis Sequence Types 1...
Visit a quote page and your recently viewed tickers will be displayed here.
Track Intervacc and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.
Browse news for competitors to Intervacc and other trending companies.